E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Selected papers from the 11th National Meeting of Organic Chemistry and 4th Meeting of Therapeutic Chemistry in Portugal"

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 August 2016)

Special Issue Editors

Guest Editor
Prof. Dr. Victor Freitas

Faculty of sciences, University of Porto, Rua do Campo Alegre, s/n, 4169-007 Porto, Portugal
Website | E-Mail
Interests: polyphenols; organic synthesis; spectroscopic methods; chromatography; natural compounds; food chemistry; color; taste
Guest Editor
Prof. Maria Emília de Sousa

1. Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal
2. Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR/CIMAR), Universidade do Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos, S/N 4450-208 Matosinhos, Portugal
Website | E-Mail
Interests: medicinal chemistry; organic synthesis; heterocycles, P-glycoprotein; anticancer; anticoagulants; chiral drugs

Special Issue Information

Dear Colleagues,

For the first time in Portugal, the competences of two important fields of Chemistry, Organic Chemistry and Medicinal Chemistry, were brought together into a joint meeting in 2015 under the auspices of Portuguese Chemical Society (SPQ). Selected papers are welcome to highlight the different research fields presented. Pharmaceuticals now invites valuable contributions that report original observations or reviews.

For more information about this meeting, please refer to: http://11enqo.eventos.chemistry.pt/.

Prof. Dr. Victor Freitas
Dr. Maria Emília de Sousa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

View options order results:
result details:
Displaying articles 1-3
Export citation of selected articles as:

Review

Jump to: Other

Open AccessFeature PaperReview Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives
Pharmaceuticals 2016, 9(4), 71; doi:10.3390/ph9040071
Received: 18 August 2016 / Revised: 2 November 2016 / Accepted: 2 November 2016 / Published: 10 November 2016
Cited by 4 | PDF Full-text (561 KB) | HTML Full-text | XML Full-text
Abstract
Multidrug resistance (MDR) presents a serious challenge to the efficiency of cancer treatment, and may be associated with the overexpression of drug efflux pumps. P-glycoprotein (P-gp) is a drug efflux pump often found overexpressed in cases of acquired MDR. Nevertheless, there are no
[...] Read more.
Multidrug resistance (MDR) presents a serious challenge to the efficiency of cancer treatment, and may be associated with the overexpression of drug efflux pumps. P-glycoprotein (P-gp) is a drug efflux pump often found overexpressed in cases of acquired MDR. Nevertheless, there are no P-gp inhibitors being used in the current clinical practice, due to toxicity problems, drug interactions, or pharmacokinetic issues. Therefore, it is important to identify novel inhibitors of P-gp activity or expression. Curcumin is a secondary metabolite isolated from the turmeric of Curcuma longa L. which has been associated with several biological activities, particularly P-gp modulatory activity (by inhibiting both P-gp function and expression). However, curcumin shows extensive metabolism and instability, which has justified the recent and intensive search for analogs of curcumin that maintain the P-gp modulatory activity but have enhanced stability. This review summarizes and compares the effects of curcumin and several curcumin analogs on P-glycoprotein function and expression, emphasizing the potential of these molecules for the possible development of safe and effective inhibitors of P-gp to overcome MDR in human cancer. Full article
Figures

Figure 1

Open AccessFeature PaperReview Chemical Variations on the p53 Reactivation Theme
Pharmaceuticals 2016, 9(2), 25; doi:10.3390/ph9020025
Received: 13 April 2016 / Revised: 6 May 2016 / Accepted: 9 May 2016 / Published: 13 May 2016
Cited by 6 | PDF Full-text (5261 KB) | HTML Full-text | XML Full-text
Abstract
Among the tumor suppressor genes, p53 is one of the most studied. It is widely regarded as the “guardian of the genome”, playing a major role in carcinogenesis. In fact, direct inactivation of the TP53 gene occurs in more than 50% of malignancies,
[...] Read more.
Among the tumor suppressor genes, p53 is one of the most studied. It is widely regarded as the “guardian of the genome”, playing a major role in carcinogenesis. In fact, direct inactivation of the TP53 gene occurs in more than 50% of malignancies, and in tumors that retain wild-type p53 status, its function is usually inactivated by overexpression of negative regulators (e.g., MDM2 and MDMX). Hence, restoring p53 function in cancer cells represents a valuable anticancer approach. In this review, we will present an updated overview of the most relevant small molecules developed to restore p53 function in cancer cells through inhibition of the p53-MDMs interaction, or direct targeting of wild-type p53 or mutated p53. In addition, optimization approaches used for the development of small molecules that have entered clinical trials will be presented. Full article
Figures

Other

Jump to: Review

Open AccessMeeting Report 11th National Meeting of Organic Chemistry and 4th Meeting of Therapeutic Chemistry
Pharmaceuticals 2016, 9(1), 15; doi:10.3390/ph9010015
Received: 23 February 2016 / Accepted: 26 February 2016 / Published: 17 March 2016
PDF Full-text (13853 KB) | HTML Full-text | XML Full-text
Abstract
For the first time under the auspices of Sociedade Portuguesa de Química, the competences of two important fields of Chemistry are brought together into a single event, the 11st National Organic Chemistry Meeting and the the 4th National Medicinal Chemistry Meeting, to highlight
[...] Read more.
For the first time under the auspices of Sociedade Portuguesa de Química, the competences of two important fields of Chemistry are brought together into a single event, the 11st National Organic Chemistry Meeting and the the 4th National Medicinal Chemistry Meeting, to highlight complementarities and to promote new synergies. Abstracts of plenary lectures, oral communications, and posters presented during the meeting are collected in this report. Full article
Back to Top